Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Bollard CM, Gottschalk S, Helen Huls M, Leen AM, Gee AP, Rooney CM.

Cytotherapy. 2011 May;13(5):518-22. doi: 10.3109/14653249.2011.561983. Epub 2011 Mar 1. No abstract available.

PMID:
21361747
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Ramos C, Fayad L, Shpall EJ, Pro B, Liu H, Wu MF, Lee D, Sheehan AM, Zu Y, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16.

PMID:
24344220
[PubMed - indexed for MEDLINE]
3.

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.

Bollard CM, Gottschalk S, Leen AM, Weiss H, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, Gee AP, Brenner MK, Rooney CM, Heslop HE.

Blood. 2007 Oct 15;110(8):2838-45. Epub 2007 Jul 3.

PMID:
17609424
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.

Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.

Oncol Rep. 2004 Oct;12(4):725-31.

PMID:
15375491
[PubMed - indexed for MEDLINE]
5.

Targeting Epstein-Barr virus-associated lymphomas.

Nikiforow S, Lacasce AS.

J Clin Oncol. 2014 Mar 10;32(8):830-2. doi: 10.1200/JCO.2013.53.2994. Epub 2014 Feb 3. No abstract available.

PMID:
24493729
[PubMed - indexed for MEDLINE]
6.

The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.

Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A, Gottschalk S, Brenner MK, Heslop HE, Rooney CM.

J Immunother. 2004 Jul-Aug;27(4):317-27.

PMID:
15235393
[PubMed - indexed for MEDLINE]
7.

Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.

Sun Q, Burton R, Reddy V, Lucas KG.

Br J Haematol. 2002 Sep;118(3):799-808.

PMID:
12181048
[PubMed - indexed for MEDLINE]
8.

EBV-associated lymphomas in adults.

Roschewski M, Wilson WH.

Best Pract Res Clin Haematol. 2012 Mar;25(1):75-89. doi: 10.1016/j.beha.2012.01.005. Epub 2012 Feb 5. Review.

PMID:
22409825
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M.

Blood. 2010 Nov 11;116(19):3695-704. doi: 10.1182/blood-2010-06-292268. Epub 2010 Jul 29.

PMID:
20671118
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A, Sixbey J, Gresik MV, Carrum G, Hudson M, Dilloo D, Gee A, Brenner MK, Rooney CM, Heslop HE.

J Exp Med. 2004 Dec 20;200(12):1623-33.

PMID:
15611290
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.

Yang D, Shao Q, Sun H, Mu X, Gao Y, Jiang R, Hou J, Yao K, Chen Y, Sun B.

Clin Dev Immunol. 2011;2011:716926. doi: 10.1155/2011/716926. Epub 2011 Sep 28.

PMID:
21969838
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.

Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM.

Recent Results Cancer Res. 2002;159:123-33.

PMID:
11785836
[PubMed - indexed for MEDLINE]
13.

Induction of the Epstein-Barr virus latent membrane protein 2 antigen-specific cytotoxic T lymphocytes using human leukocyte antigen tetramer-based artificial antigen-presenting cells.

Lu XL, Liang ZH, Zhang CE, Lu SJ, Weng XF, Wu XW.

Acta Biochim Biophys Sin (Shanghai). 2006 Mar;38(3):157-63.

PMID:
16518539
[PubMed - indexed for MEDLINE]
Free Article
14.

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S.

J Clin Oncol. 2005 Dec 10;23(35):8942-9. Epub 2005 Oct 3.

PMID:
16204009
[PubMed - indexed for MEDLINE]
15.

Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG.

Blood. 2000 Feb 1;95(3):807-14.

PMID:
10648390
[PubMed - indexed for MEDLINE]
Free Article
16.

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

Comoli P, De Palma R, Siena S, Nocera A, Basso S, Del Galdo F, Schiavo R, Carminati O, Tagliamacco A, Abbate GF, Locatelli F, Maccario R, Pedrazzoli P.

Ann Oncol. 2004 Jan;15(1):113-7.

PMID:
14679129
[PubMed - indexed for MEDLINE]
Free Article
17.

Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.

Murray RJ, Wang D, Young LS, Wang F, Rowe M, Kieff E, Rickinson AB.

J Virol. 1988 Oct;62(10):3747-55.

PMID:
2843672
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Sili U, Leen AM, Vera JF, Gee AP, Huls H, Heslop HE, Bollard CM, Rooney CM.

Cytotherapy. 2012 Jan;14(1):7-11. doi: 10.3109/14653249.2011.636963.

PMID:
22172091
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.

Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.

Eur J Immunol. 2006 Mar;36(3):593-602.

PMID:
16479544
[PubMed - indexed for MEDLINE]
20.

EBV-related lymphomas: new approaches to treatment.

Kanakry JA, Ambinder RF.

Curr Treat Options Oncol. 2013 Jun;14(2):224-36. doi: 10.1007/s11864-013-0231-y.

PMID:
23549980
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk